Health
New study shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer. – Brinkwire
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell lung cancer (NSCLC), suggesting a possible new approach to treating cancers that have developed resistance to the targeted EGFR inhibitor osimertinib.
The data is published today in Cancer Research, a journal of the American Associat…
-
General17 hours agoTributes flow after Australian Paralympic bronze medallist Nicholas Hum dies aged 32
-
General12 hours agoReuven Morrison was killed in the Bondi Beach shooting one year after warning about antisemitism
-
General13 hours agoNT’s top year 12 achievers celebrated, with some looking to pursue teaching careers
-
General21 hours agoLondon plane trees to be removed in Hamilton following infrastructure concerns